Agilvax

United States
Chico, California, United States, 87110

Company profile

Agilvax company profile

Agilvax is a private company that discovers and develops immunotherapies to combat cancer and targeted vaccines against infectious diseases. The company identifies and selects lead vaccine candidates through its proprietary affinity optimizes those by in vitro and in vivo testing and develops them through pre-clinical and/or clinical testing until proof of concept is achieved establishing attractive out-licensing opportunities to Pharma or Biotech partners. Collaborations and partnerships are actively pursued within the industry, academia, and the government sector through NIAID.

Business identity

Contact email
[email protected]
Phone number
5057974531
Operating status
Closed
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2011-01-01, Year

Headquarters

Postal code
87110
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
6
Total equity funding
$6.5M
Last funding
Series A / $1.5M / 2020-01-17
Last equity funding
Series A / $1.5M
Investors
4
Lead investors
2
Founders
2
Articles
3
Closed on
2021-08-12

Founders and investors

Founders

Bryce ChackerianDavid Peabody

Lead investors

JHH vcNational Cancer Institute SBIR Development Center

Investors

JHH vcNational Cancer Institute SBIR Development CenterNational Cancer Research InstituteSun Mountain Capital